All Stories

  1. Genetic Testing is Superior Over Endogenous Pharmacometabolomic Markers to Predict Safety of Haloperidol in Patients with Alcohol-induced Psychotic Disorder

    Article • Current Drug Metabolism, November 2022, Bentham Science Publishers

    Valentin Skryabin

  2. How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?

    Article • Drug Metabolism and Personalized Therapy, March 2020, De Gruyter

    Valentin Skryabin

  3. Chemsex in Moscow: investigation of the phenomenon in a cohort of men who have sex with men hospitalized due to addictive disorders

    Article • International Journal of STD & AIDS, February 2020, SAGE Publications

    Valentin Skryabin

  4. Hallucinogen persisting perception disorder: A literature review and three case reports

    Article • Journal of Addictive Diseases, October 2019, Taylor & Francis

    Valentin Skryabin

  5. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder

    Article • Canadian Journal of Physiology and Pharmacology, August 2019, Canadian Science Publishing

    Valentin Skryabin

  6. Clinical characteristics of synthetic cannabinoid-induced psychotic disorders: a single-center analysis of hospitalized patients

    Article • Journal of Addictive Diseases, July 2019, Taylor & Francis

    Valentin Skryabin

  7. Pharmacogenetics of alcohol addiction: current perspectives

    Article • The Application of Clinical Genetics, July 2019, Dove Medical Press

    Professor Dmitry Alexeevich Sychev, Valentin Skryabin

  8. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder

    Article • Drug Metabolism and Personalized Therapy, December 2018, De Gruyter

    Valentin Skryabin

  9. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers

    Article • Human Psychopharmacology Clinical and Experimental, October 2018, Wiley

    Valentin Skryabin

  10. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

    Article • Pharmacogenomics and Personalized Medicine, June 2018, Dove Medical Press

    Professor Dmitry Alexeevich Sychev, Valentin Skryabin

  11. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder

    Article • Pharmacogenomics and Personalized Medicine, July 2017, Dove Medical Press

    Professor Dmitry Alexeevich Sychev, Valentin Skryabin

  12. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration

    Article • Drug Metabolism and Personalized Therapy, January 2017, De Gruyter

    Valentin Skryabin